Mark N. Gaze

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 185 citations

Medicine, Oncology, Pharmacology +13

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

J. Gains, Jamshed Bomanji, Naomi Fersht et al. · Journal of Nuclear Medicine · 2011 · 163 citations · Full text

Medicine, Nuclear Medicine, Oncology +15

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · Cancers · 2020 · 145 citations · Full text

Medicine, Oncology, Surgery +15